News

CoronaVac COVID-19 Vaccine Less Effective in Scleroderma in Brazil

People with systemic sclerosis (SSc) in Brazil had a weaker immune response to the CoronaVac COVID-19 vaccine than did healthy individuals, a study discovered. The findings also showed that treatment with the immunosuppressant therapy CellCept (mycophenolate mofetil) — an oral medication that improves lung function in SSc patients…

New Risk Factors for Diastolic Dysfunction Identified in Study

Several risk factors for diastolic dysfunction (DD), the heart’s inability to fill with blood properly after it beats, were identified in people with systemic sclerosis (SSc) in a recent study. These risk factors, such as obesity, could be potentially modified to reduce the occurrence of more serious disease outcomes,…

CAN10 Counters Scleroderma Development in Preclinical Study

Cantargia’s investigational antibody treatment, CAN10, showed promise in an animal model of systemic sclerosis (or scleroderma), normalizing several biological indicators of disease and counteracting disease development in the skin and lungs. “We are excited about these new results, showing strong effects of CAN10 in a systemic sclerosis model.

Prepare to Light Up Buildings for Rare Disease Day 2022

The National Organization for Rare Disorders (NORD) asks Americans to plan ahead to participate in the Light Up for Rare campaign to raise awareness of rare diseases. NORD is the U.S. sponsor for Rare Disease Day on Feb. 28. The annual awareness day spotlights approximately 7,000…